Business Context and Reporting Period
This Form 8-K Current Report was filed by Lifemd, Inc. on July 30, 2021, with the report date signed on August 4, 2021. The filing pertains to corporate governance matters, specifically the renewal of a director agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.
Material Changes
The primary material change reported is the execution of a Renewed Director Agreement between Lifemd, Inc. and Roberto Simon, effective July 30, 2021. This agreement supersedes the prior agreement dated November 6, 2020.
Management Commentary and Compensation Details
Under the new agreement, Mr. Simon, serving as a Board member and Chairman of the Audit Committee, will receive the following compensation:
- Equity Grant: 10,000 restricted stock units (RSUs) vesting quarterly beginning September 30, 2021, pursuant to the Company's Employee Stock Option Plan.
- Cash Compensation: $6,000 per quarter for his services.
- Indemnification: The Company agrees to indemnify, defend, and hold Mr. Simon harmless to the fullest extent permitted by Delaware law.
The filing notes that the description of the agreement is brief and refers investors to the full text of the Director Agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 10,000 RSU grant on dilution.
- Review the full text of the Renewed Director Agreement (Exhibit 10.1) for specific vesting conditions and termination clauses.
- Confirm the status of any prior compensation owed to Mr. Simon under the November 2020 agreement.
- Check subsequent filings for the actual vesting schedule execution starting September 30, 2021.